We are live on ! Find out more
SCMP

Sucampo Pharmaceuticals, Inc.
SCMP

Delisted

SCMP was delisted on the 12th of February, 2018.

165 hedge funds and large institutions have $340M invested in Sucampo Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 54 increasing their positions, 43 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

588% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 8

48% more capital invested

Capital invested by funds: $229M → $340M (+$111M)

39% more funds holding

Funds holding: 119165 (+46)

26% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 43

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

39% less call options, than puts

Call options by funds: $1.17M | Put options by funds: $1.91M

Holders
165
Holders Change
+46
Holders Change %
+38.66%
% of All Funds
4.13%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
55
Increased
54
Reduced
43
Closed
8
Calls
$1.17M
Puts
$1.91M
Net Calls
-$737K
Net Calls Change
-$936K
Name Holding Trade Value Shares
Change
Change in
Stake
IA
51
Icon Advisers
Colorado
$1.12M -$86.5K -6,200 -7%
Barclays
52
Barclays
United Kingdom
$1.05M +$1.07M +76,727 +16,753%
MSU
53
Mizuho Securities USA
New York
$1.02M +$1.05M +75,000 New
SM
54
Sabby Management
Florida
$1.02M +$1.05M +75,000 New
Bank of America
55
Bank of America
North Carolina
$993K +$229K +16,425 +29%
OAM
56
Oberweis Asset Management
Illinois
$945K +$205K +14,700 +27%
Wells Fargo
57
Wells Fargo
California
$933K -$248K -17,789 -21%
Two Sigma Advisers
58
Two Sigma Advisers
New York
$921K +$176K +12,600 +23%
Tudor Investment Corp
59
Tudor Investment Corp
Connecticut
$919K +$946K +67,811 New
Macquarie Group
60
Macquarie Group
Australia
$913K
NFA
61
Nationwide Fund Advisors
Ohio
$911K +$720K +51,621 +330%
PCM
62
Piermont Capital Management
Missouri
$894K -$18.3K -1,310 -2%
SAM
63
Shell Asset Management
Netherlands
$878K -$7.88K -565 -0.9%
BGIM
64
Brandywine Global Investment Management
Pennsylvania
$871K -$402K -28,838 -31%
PPA
65
Parametric Portfolio Associates
Washington
$836K +$184K +13,172 +27%
Citadel Advisors
66
Citadel Advisors
Florida
$834K +$383K +27,433 +80%
MFS
67
MSI Financial Services
Massachusetts
$819K +$843K +60,461 New
GC
68
Globeflex Capital
California
$814K +$657K +47,100 +364%
CCMG
69
Clark Capital Management Group
Pennsylvania
$800K +$824K +59,044 New
LPL Financial
70
LPL Financial
California
$776K +$776K +55,600 New
GAM
71
Gotham Asset Management
New York
$752K +$774K +55,508 New
CAM
72
ClariVest Asset Management
California
$743K +$764K +54,800 New
JG
73
Jefferies Group
New York
$741K +$763K +54,700 New
EGM
74
Engineers Gate Manager
New York
$727K +$748K +53,648 New
UBS Group
75
UBS Group
Switzerland
$713K +$317K +22,749 +76%

SCMP Hedge Fund Activity: Q4 2016 in Review

165 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Sucampo Pharmaceuticals, Inc. (SCMP) for Q4 2016, worth a combined $340M — up 48% from $229M a quarter earlier.

Buyers outnumbered sellers: 55 funds opened new SCMP positions and 8 closed out — a net gain of 47 holders — while 54 added to existing stakes and 43 trimmed.

The largest buyer was Redwood Investments, opening a new position worth an estimated $8.42M. The largest seller was Boston Partners, exiting entirely with an estimated $2.94M sold.

  • 165 institutional investors held Sucampo Pharmaceuticals, Inc. (SCMP) as of Q4 2016, up from 119 in Q3 2016.
  • Funds reported $340M of Sucampo Pharmaceuticals, Inc. stock for Q4 2016, up 48% quarter-over-quarter.
  • 55 funds opened new Sucampo Pharmaceuticals, Inc. positions in Q4 2016 and 8 closed out, a net change of +47 holders.
  • The largest Sucampo Pharmaceuticals, Inc. buyer in Q4 2016 was Redwood Investments, an estimated $8.42M added.
  • The largest Sucampo Pharmaceuticals, Inc. seller in Q4 2016 was Boston Partners, an estimated $2.94M sold.

Based on aggregated 13F filings for Q4 2016.